[Radiologic follow-up and prognosis of efficiency of systemic Sr-89 Cl-2 therapy of bone metastases in prostate cancer].
We evaluated possibilities of bone scintigraphy with 99mTc-methylendiphosphonate (99mTc-MDP) and magnetic resonance imaging (MRI) in follow-up and prediction of effect in patients with extensive bone metastatic disease treated with betha-emitter 89SrCl2. 24 patients with prostate cancer and extensive metastatic involvement of skeleton were referred for the study. 89SrCl2 was injected as single injection of 150 MBq (4 mCi), in eighteen from Amersham plc., England, as Metastron, in six--from Medradiopreparat, Russia). In all patients bone scintigraphy with 99mTc-MDP and MRI study of metastatic regions were performed before and in 3 months after 89SrCl2 injection. Patients treated with Metsatron were also studied in 6 months after injection. Quantitative analysis of data comprised count and anatomic dimensions of metastatic areas and calculation of indices [metastasis/intact bone] both for scintillation count of 99mTc-MDP bone scans and signal intensity of T1-weighted MRI scan. Henceforth, we conclude the data of bone scanning with 99mTc-MDP and of MRI give evidencies for significant regress of bone metastases in patients treated with 89SrCl2 besides symptomatic suppression of pain syndrome. 99mTc-MDP bone scanning is also of predictive value for the prognosis of therapeutic effect of systemic radiotherapy with 89SrCl2 in prostate cancer.
Barysheva
E V
EV
Institutes of Cardiology and Oncology, Tomsk Medical Research Center.
Obradovic
V
V
Stefanovic
L
L
Riannel'
Iu E
IuE
Regoe
S
S
Selivanov
S P
SP
Artiko
V
V
Isaeva
S N
SN
Velichko
S A
SA
Tuzikov
S A
SA
Ussov
V Iu
VIu
D000368:Aged; D001859:Bone Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000532:radiotherapy* / Q000556:secondary*; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D011879:Radiotherapy Dosage; D013324:Strontium / Q000627:therapeutic use*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate; D013997:Time Factors
D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; C025700:strontium chloride; D013669:Technetium Tc 99m Medronate; D013324:Strontium
Kompleksnaia luchevaia otsenka i prognozirovanie éffektivnosti sistemnoĭ radioterapii 89SrCl2 pri kostnykh metastazakhraka predstatel'noĭ zhelezy.